Review

Apuntes

Review Pharmacotherapy of obesity: an update on the available medications and drugs under investigation Marlene Chakhtoura,a Rachelle Haber,a Malak Ghezzawi,a Caline Rhayem,a Raya Tcheroyan,b and Christos S. Mantzorosc,∗ aDivision of Endocrinology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon bFaculty of Medicine and Medical Center, American University of Beirut, Beirut, Lebanon cBeth Israel Deaconess Medical Center and Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA Summary Obesity is an epidemic and a public health threat. Medical weight management remains one of the options for the treatment of excess weight and recent advances have revolutionized how we treat, and more importantly how we will be treating obesity in the near future. Metreleptin and Setmelanotide are currently indicated for rare obesity syn- dromes, and 5 other medications (orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide) are approved for non-syndromic obesity. Tirzepatide is about to be approved, and other drugs, with exciting novel mechanisms of action primarily based on incretins, are currently being investi...